EP Patent

EP4487839A1 — Pharmaceutical dosage form comprising trientine tetrahydrochloride, and method for preparing the same

Assigned to Alfred E Tiefenbacher GmbH and Co KG · Expires 2025-01-08 · 1y expired

What this patent protects

The present invention relates to a pharmaceutical dosage form of trientine tetrahydrochloride that has low stickiness and good fluidity, and that can be stably manufactured. The pharmaceutical dosage form comprises crystalline trientine tetrahydrochloride and at least one pharmac…

USPTO Abstract

The present invention relates to a pharmaceutical dosage form of trientine tetrahydrochloride that has low stickiness and good fluidity, and that can be stably manufactured. The pharmaceutical dosage form comprises crystalline trientine tetrahydrochloride and at least one pharmaceutically acceptable excipient. Moreover, the present invention relates to a method of preparing the pharmaceutical dosage form.

Drugs covered by this patent

Patent Metadata

Patent number
EP4487839A1
Jurisdiction
EP
Classification
Expires
2025-01-08
Drug substance claim
No
Drug product claim
No
Assignee
Alfred E Tiefenbacher GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.